is a potent and selective agonist of the human ␤ 3 -adrenergic receptor. We report herein the data from studies of the metabolism and excretion of 1 in rats. Five metabolites were identified in the bile of male SpragueDawley rats administered 3 H-labeled 1 by either oral gavage (10 mg/kg) or intravenous injection (3 mg/kg). These included a pyridine N-oxide derivative (M2), a primary amine resulting from N-dealkylation and loss of the pyridinyl-2-hydroxyethyl group (M4), a carboxylic acid derived from N-dealkylation and loss of the pyridyl-2-hydroxyethyl amine (M5), and the corresponding taurine and isethionic acid conjugates (M1 and M3). Metabolites M1 and M3 also were identified in rats treated with M5 and were generated in incubations of M5 with rat liver subcellular fractions in the presence of ATP and coenzyme A with supplementary taurine or isethionic acid. These results suggest that M5 is the precursor of M1 and M3 and that the formation of these conjugated metabolites follows similar mechanisms of amino acid conjugation. On the other hand, M2, M4, and M5 were produced from 1 in an NADPHdependent manner in incubations with liver microsomes from rats, dogs, monkeys, and humans. In human liver preparations, these routes of biotransformation were shown to be catalyzed by cytochrome P450 3A4. In a bidirectional transport assay, transport of 1 across a monolayer of cells expressing P-glycoprotein (Pgp) was observed to be similar to that of vinblastine, which is an established substrate of the transporter protein. This finding, together with the observation that the parent compound was excreted in the feces of bile duct-cannulated animals following intravenous dosing, suggests that 1 is subject to Pgp-mediated excretion from intestine of rats.
Increased concerns in the United States and in many other countries have been focused on obesity, which in many cases is the prelude to developing more severe disorders such as Type II diabetes, hypertension, and cardiovascular diseases (Eckel and Krauss, 1998; Wickelgren, 1998) . Obesity is the result of an imbalance between caloric intake and energy expenditure; excess energy is therefore accumulated in the form of triglycerides in adipocytes, and this accumulation increases with the expansion of adipose tissues. In general, mechanisms for treatment of obesity include increasing energy consumption, stimulating fat metabolism, and reducing nutrient intake (Campfield et al., 1998; Kordik and Reitz, 1999) . The discovery of a unique ␤-adrenergic receptor subtype, namely the ␤3 receptor, on the surface of adipocytes that stimulates lipolysis has led to speculation that a selective agonist of the ␤ 3 -adrenergic receptor may be used for treating obesity (Danforth and Himms-Hagen, 1997; Weyer et al., 1999) . In experimental animals, treatment with agonists of the ␤ 3 -adrenergic receptor led to increases in metabolic rate, weight loss, and improved glucose tolerance (Bloom et al., 1992; Cawthorne et al., 1992) . Similar studies in human trials, however, were inconclusive, and results were complicated by the lack of selectivity of the agonists studied for the ␤ 3 receptor versus the ␤ 1 /␤ 2 receptors (Weyer et al., 1999) . Further investigation indicated that the homology between rodent and human ␤ 3 -adrenergic receptors was high whereas differences in the pharmacology of these receptors were apparent (PietriRouxel and Strosberg, 1995; Lipworth, 1996) . On the other hand, a small population of human subjects carrying a mutated ␤ 3 receptor were identified and reported to have tendency to gain weight and exhibit an earlier onset of noninsulin-dependent diabetes (Clement et al., 1995; Walston et al., 1995) . These data suggest that a potential therapeutic agent for the treatment of obesity would need to be potent and selective toward the human ␤ 3 -adrenergic receptor.
The structures and pharmacokinetic properties of several agonists of the human ␤ 3 -adrenergic receptor have been described (Mathvink et al., 1999; Shih et al., 1999) . In addition, (R)-N- [4-[2-[[2-hydroxy-2-(pyridin-3-yl) Fig. 1 ), a nanomolar ag-onist of the human ␤ 3 -adrenergic receptor with a 1000-fold selectivity over ␤ 1 and ␤ 2 receptors, has been reported (Mathvink et al., 2000) , and its pharmacokinetic characteristics described in the preceding article (Stearns et al., 2002) . We report herein the results derived from studies of the biotransformation and excretion of 1 in bile ductcannulated rats. Five major metabolites, including a taurine conjugate and a novel isethionic acid conjugate, were characterized by liquid chromatography/tandem mass spectrometry (LC/MS/MS). These metabolites were further investigated in vitro with respect to their mechanisms of formation, whereas the parent compound 1 was evaluated for P-glycoprotein (Pgp)-mediated transport.
Experimental Procedures
Materials. Anilino-2-3 H-labeled 1 and 1 hydrochloride were synthesized at Merck Research Laboratories (Mathvink et al., 2000; Stearns et al., 2002) . The specific activity of 3 H-labeled 1 was 1750 mCi/mmol with a radiochemical purity greater than 97%. [ 3 H]Vinblastine was obtained from Amersham Pharmacia Biotech, Inc. (Piscataway, NJ). Coenzyme (CoA), dithiothreitol, HEPES, isethionic acid, magnesium chloride, monoamine oxidase (EC 1.4.3.4.), NADPH, quinidine, taurine, trifluoroacetic acid, and troleandomycin were purchased from Sigma-Aldrich (St. Louis, MO). All other reagents and solvents were obtained from Fisher Scientific (Fair Lawn, NJ) or Aldrich Chemical Co. (Milwaukee, WI). BondElut C 18 solid phase extraction cartridge columns were obtained from Varian Chromatography Systems (Walnut Creek, CA). Sulfaphenazole was a gift from Dr. F. P. Guengerich (Vanderbilt University, Nashville, TN).
The following recombinant cytochrome P450 (P450) enzymes were purchased from Gentest Corp. (Woburn, MA): microsomes from a baculovirusinsect cell line expressing human P450 (CYP)2C9 or 3A4 (ϩb5); microsomes from a human lymphoblast cell line expressing human CYP1A2, 2A6, 2C8, 2C19, 2D6, or 2E1.
Monoclonal antibodies against human hepatic CYP3A4 or 2D6 were products of hybridomas derived from the fusion of myeloma cells and spleen cells from mice immunized with baculovirus-expressed CYP3A4 or 2D6 (Mei et al., 1999) .
Porcine kidney epithelial cells expressing human or mouse Pgp were obtained from Dr. A. H. Schinkel (The Netherlands Cancer Institute, Amsterdam, The Netherlands).
Instrumentation and Analytic Methods. LC/MS/MS was carried out on a Sciex API III ϩ tandem mass spectrometer (PerkinElmer, Ontario, Canada) interfaced to an HPLC system consisting of two Shimadzu LC-10A pumps and a static-bed mixer (Shimadzu Scientific Instruments, Kyoto, Japan). LC/ MS/MS experiments were performed with an ion spray interface and positive ion detection. The voltage was 5 kV, and orifice potential was 65 V. Argon was used as the collision gas for collision-induced dissociation (CID) at a thickness of 1.3 ϫ 10 14 atom/cm 2 , and the collision energy was 30 eV. Chromatography was performed on a DuPont Zorbax Rx-C 8 column (4.6 ϫ 250 mm, 5 m; DuPont, Wilmington, DE), and samples were delivered at a rate of 1 ml/min with 1:25 split. The mobile phase consisted of aqueous acetonitrile (10% methanol and 0.05% trifluoroacetic acid) and was programmed by a linear increase from 10 to 70% acetonitrile during a 30-min period with isocratic elution at 70% acetonitrile for a further 10 min. Product ion scans were performed on selected MH ϩ ions at a scan speed of ϳ1 s per 225 atomic mass units. Multiple reaction monitoring detection (MRM) was based on one mass transition per metabolite at dwell times of 400 ms per channel.
HPLC was performed on a Shimadzu LC-10AD liquid chromatograph with a DuPont Zorbax Rx-C 8 column (4.6 ϫ 250 mm, 5 m) at a flow rate of 1 ml/min. The mobile phase consisted of aqueous acetonitrile (10% methanol and 0.05% trifluoroacetic acid) and was programmed by a linear increase from 10 to 70% acetonitrile during a 30 min period followed by isocratic elution with 70% acetonitrile for an additional 10 min. Ultraviolet detection was at 250 and 280 nm. For radiolabeled samples, fractions were collected every minute during the HPLC run, and the radioactivity was determined by a Beckman 3801 liquid scintillation counter (Beckman Coulter, Inc., Fullerton, CA) in borosilicate vials containing ScintiSafe Gel (Fisher Scientific).
Synthesis of Metabolites of 1. M2. A slurry of 1 (625 mg) in anhydrous tetrahydrofuran (6 ml) was cooled in an ice-methanol bath and treated with di-tert-utyl dicarbonate (1 ml, 1.0 M in tetrahydrofuran), and the mixture was slowly warmed to room temperature over 3 h. The resulting pale yellow solution was concentrated in vacuo, and the residue (320 mg) was dissolved in chloroform (10 ml) and cooled in an ice-water bath. m-Chloroperbenzoic acid (123 mg, 80 -85% wt.) was added, and the solution was warmed to room temperature over a 2-h period. Solvent was removed under reduced pressure, and the resulting pale yellow foam was dissolved in dichloromethane (15 ml). Trifluoroacetic acid (4 ml) was added, and the solution stirred at room temperature for 1.5 h. Volatiles were removed under reduced pressure, and the residue was purified by preparative thin-layer chromatography (silica gel; 19:1 methylene chloride:10% ammonium hydroxide-methanol eluant) to afford the title compound (264 mg) as an off-white foam. M4. A solution of 2-(4-aminophenyl)ethylcarbamic acid tert-utyl ester (142 mg) and pyridine (80 l) in dichloromethane (5 ml) was treated with 4-{4-[4-(trifluoromethyl)phenyl]-5-trimethylsilyl-1,3-thiazol-2-yl}benzenesulfonyl chloride (286 mg), and the resulting solution was stirred at room temperature for 2 h. Volatiles were removed in vacuo, and the residue was taken up in acetonitrile (8 ml) and treated with hydrogen fluoride in aqueous acetonitrile (7 ml; 4.8%; water/acetonitrile, 15:85, v/v) . The mixture was stirred vigorously for 5 h and was then concentrated in vacuo. The residue was purified by flash chromatography (silica gel; 9:1 methylene chloride:10% ammonium hydrox- M5. A solution of 4-nitrophenylacetic acid (1.82 g) was added to a solution of acetyl chloride (1.0 ml) in methanol (25 ml), and the mixture was subsequently heated to reflux. After 3 h, the solution was cooled and concentrated under reduced pressure. The residue was partitioned between water and ether, and the ether layer was washed sequentially with saturated aqueous sodium bicarbonate and saturated brine. Drying with anhydrous magnesium sulfate and removal of solvent gave a white solid (1.85 g), which was dissolved in ethyl acetate (25 ml) and treated with 10% palladium on carbon (110 mg). The mixture was shaken under 50 psi of hydrogen for 1 h, then filtered through a pad of Celite, and concentrated in vacuo. The resulting cloudy mobile oil (1.66 g) was used directly in the next step. This oil (290 mg) in dichloromethane (10 ml) was treated sequentially with pyridine (0.13 ml) and 4-{4-[4-(trifluoromethyl)phenyl]-5-trimethylsilyl-1,3-thiazol-2-yl}benzenesulfonyl chloride (715 mg). The mixture was stirred at room temperature for 2 h and was then concentrated in vacuo. The residue was dissolved in acetonitrile (5 ml), and hydrogen fluoride in aqueous acetonitrile (8 ml; 4.8%; water/acetonitrile, 15:85, v/v) was added. The mixture was stirred at room temperature overnight and was then concentrated in vacuo. The residue was stirred with methanol (30 ml) for 1 h, and the solid was collected and washed with methanol to afford a pale pink solid (307 mg). The combined filtrates were concentrated in vacuo, and the residue was purified by flash chromatography (silica gel; 25% ethyl acetate-hexanes eluant) to provide an additional product (483 mg). The combined batches were dissolved in tetrahydrofuran/methanol/water (8 ml; 3:2:1, v/v/v), and lithium hydroxide monohydrate (153 mg) was added. After stirring at room temperature for 1 h, an additional quantity of lithium hydroxide monohydrate (153 mg) was added, and the solution was stirred for a further 1.5 h. Volatiles were removed under reduced pressure, and water (20 ml) was added. The solution was washed with ether, then cooled in ice, neutralized to pH 4 with 5% aqueous hydrochloric acid, and extracted with ethyl acetate. The combined organic extracts were washed with saturated brine, dried with anhydrous magnesium sulfate, and concentrated to an off-white solid. Trituration with hexanes provided a white powder (645 mg).
1 H NMR (400 MHz,
M1. A mixture of M5 (51 mg) in dry N,N-dimethylformamide (1.0 ml) was cooled to 0°C, and diphenylphosphoryl azide (24 l) was added, followed by triethylamine (20 l). The solution was warmed to room temperature, and after 30 min it was cooled in an ice-water bath and treated with a solution of taurine (17 mg) and 1,1,3,3-tetramethylguanidine (34 l) in dry N,N-dimethylformamide (0.6 ml). The reaction mixture was allowed to slowly warm to room temperature overnight and was then concentrated in vacuo. The yellow oily residue was dissolved in aqueous sodium hydroxide (3 ml, 0.07 N). The aqueous solution was washed with ethyl acetate and was then concentrated in vacuo. The residue was purified by flash chromatography (silica gel; gradient elution with 9:1, then 6:1 methylene chloride:10% ammonium hydroxidemethanol eluant) to afford the title compound (27 mg) as a white powder. 
. HPLC radiohistogram (A) and UV-vis chromatogram (B) of bile from a rat treated by oral gavage with 3 H-labeled 1 (10 mg/kg); HPLC radiohistogram (C) of a feces sample from a rat treated by intravenous injection with
3 H-labeled 1 (3 mg/kg).
Characterization of M1, parent drug, M2, M3, M4, and M5 is discussed in the text.
FIG. 3. LC/MS/MS product ion spectrum of M5 in the bile from a rat dosed orally with 1.
The spectrum was obtained by CID of the MH ϩ ion at m/z 519, and the proposed origins of key fragment ions are as indicated.
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M3. A mixture of M5 (100 mg) and thionyl chloride (2 ml) was warmed at reflux for 1 h. The solution was cooled and concentrated in vacuo, and the residue was azeotroped twice with dry benzene and then dried under high vacuum. The resulting off-white solid was suspended in xylenes (2 ml), and sodium isethionate (14 mg) was added. The mixture was warmed at 145°C for 5 h, cooled to room temperature, and diluted with anhydrous ether (10 ml). The precipitate was collected by filtration, dissolved in 10% ammonium hydroxidemethanol, and purified by flash chromatography (silica gel; 9:1 methylene chloride:10% ammonium hydroxide-methanol eluant) to afford the title compound (19 mg) as a light yellow, crystalline solid. Animal Experiments. All experiments were performed according to procedures approved by the Merck Institutional Animal Care and Use Committee.
Male Sprague-Dawley rats, purchased from Harlan Sprague Dawley Inc. (Indianapolis, IN) and weighing 270 to 360 g, were allowed free access to commercial rat chow and water. They were anesthetized with Nembutal, and their bile ducts cannulated with PE-10 tubing. Control bile was collected before treatment. Three rats were dosed with 3 H-labeled 1 at 10 mg/kg by oral gavage, and three were dosed at 3 mg/kg by intravenous injection. The oral dose was dissolved in aqueous lactic acid (0.02 M) containing 10% Tween 80 (specific activity, 10 Ci/mg), and the intravenous dose was in aqueous lactic acid (0.3 M, specific activity, 10 Ci/mg). Bile, urine, and feces were collected for 120 h following the dose.
One male Sprague-Dawley rat was anesthetized with Nembutal and its bile duct cannulated with PE-10 tubing. Control bile was collected before treatment. The rat was dosed with M5 at 10 mg/kg in an aqueous solution by intraperitoneal injection. Bile was collected for an additional 8 h.
Male CF-1 mice, weighing 30 to 35 g, were from a colony maintained at Merck Research Laboratories and allowed free access to commercial mouse chow and water. They were anesthetized with Nembutal, and their bile ducts cannulated with silicon tubing (Silastic, 0.012 mm i.d. ϫ 0.025 mm o.d.; Dow Corning Corp., Midland MI). Control bile was collected before treatment. Two mice were dosed with M5 at 10 mg/kg dissolved in an aqueous solution by intraperitoneal injection. Two mice were coadministered M5 at 10 mg/kg and isethionic acid at 50 mg/kg dissolved in an aqueous solution by intraperitoneal injection. Bile was collected for an additional 8 h.
Aliquots (50 to 100 l) of bile and urine samples were acidified to pH 2 with 10% aqueous trifluoroacetic acid and injected onto the HPLC column for analysis by LC/MS. Feces (1 g) were homogenized in water (2 ml) and extracted twice with ethyl acetate (2 ϫ 5 ml). The combined extracts were dried under nitrogen and reconstituted in 60% aqueous acetonitrile (300 l). Radioactivity recovery was greater than 90%. Aliquots (80 l) of the resulting samples were injected onto the HPLC column and analyzed by LC/MS.
Biological Preparations. Human liver samples were obtained from the Pennsylvania Regional Tissue Bank (Exton, PA). An agreement was made between the tissue bank and Merck & Co. for research use of the samples.
A pooled liver mitochondrial fraction was isolated from Sprague-Dawley rats (5 male), and pooled liver microsomal fractions were isolated from 
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Sprague-Dawley rats (40 male), beagle dogs (4 male), rhesus monkeys (4 male), or humans (3 males and 2 females) by differential centrifugation (Pedersen et al., 1978; Raucy and Lasker, 1991) .
Incubations of 1 with Liver Microsomes. The hydrochloride salt of 1 in an aqueous solution was added to rat, dog, monkey, or human liver microsomes (1 mg of protein/ml) or recombinant P450 (0.5-1 mg of protein/ml) suspended in phosphate buffer (0.1 M, pH 7.4) containing EDTA (1 mM). The final volume was 0.5 ml, and substrate concentrations were from 1 to 1000 M. Microsomes containing an empty cDNA expression vector were used as negative controls. The mixture was incubated at 37°C for 5 min before adding NADPH in phosphate buffer (final concentration, 1 mg/ml) to initiate the reaction. After an additional 5 min (kinetic studies) or 30 min (metabolism studies) incubation, the reaction was quenched by adding 10% aqueous trifluoroacetic acid (60 l). Apparent K m and V max values for 1 metabolism in human liver microsomal incubations were calculated according to the Michaelis-Menten equation.
In experiments involving P450 isoform-specific inhibitors, human liver microsomes were preincubated with sulfaphenazole and quinidine for 10 min and were preincubated with troleandomycin in the presence of NADPH for 15 min at 37°C, respectively. The inhibitors were dissolved in methanol, and their final concentrations were 25 M. The same amount of solvent was added into control incubations (final concentration: 0.2%). Reactions were performed for 30 min and quenched by adding 10% aqueous trifluoroacetic acid (60 l).
In immunoinhibition experiments, human liver microsomes were preincubated with a monoclonal anti-CYP3A4 antibody for 30 min at room temperature. Control incubations contained preimmune IgG. Thereafter, the hydrochloride salt of 1 and NADPH were added and the incubations performed in a similar manner as described above.
Incubations of M5 with Rat Liver Mitochondria. Rat liver microsomes or mitochondria were suspended in Tris-buffer (100 M, pH 7.4) containing EDTA (1 mM). The protein concentrations were 4.3 mg/ml for microsomal incubations and 2.1 mg/ml for mitochondrial incubations. M5 was dissolved in 0.1 M sodium hydroxide solution and was added to the incubation suspension to give a final concentration of 1 mM. ATP (5.5 mg), CoA (0.77 mg), magnesium chloride (1 mg), and dithiothreitol (0.15 mg), all dissolved in Tris-buffer, were subsequently added to the suspension, and the final volume was 1 ml. The mixture was incubated at 37°C for 2 h. The reaction mixture then was acidified to pH 2 with 10% aqueous trifluoroacetic acid and extracted by a C 18 solid phase extraction cartridge column. The resulting samples were analyzed by LC/MS/MS.
Bidirectional Transport across Monolayers of Cells Expressing Pgp. The assay was performed according to published procedures (Kim et al., 1998) . Briefly, porcine kidney epithelial cells expressing mouse or human Pgp were seeded on polycarbonate membrane filters to form a monolayer and cultured for 4 days. The culture medium was then replaced by a serum-free transport medium consisting of Hanks' balanced salt solution and HEPES buffer (pH 7.4). The bidirectional transport assay was initiated by adding the fresh transport medium into the receiver side and adding the medium containing test compounds ([ 3 H]vinblastine or 3 H-labeled 1) into the donor side of the monolayer. Aliquots of samples were taken following incubations at 37°C for certain time intervals and subjected to liquid scintillation counting on a Beckman LS6500 multipurpose scintillation counter (Beckman Coulter, Inc.). Vectorial transport of the test compound was evaluated by the ratio of basolateral (B)-to-apical (A) versus A-to-B transport.
Results

Metabolism of 1 in Rats. After oral dosing of
3 H-labeled 1 at 10 mg/kg, 22% of the administered radioactivity was found in the bile, 6% in the urine, and 75% in the feces (Stearns et al., 2002) . After intravenous dosing at 3 mg/kg, 63% of the radioactivity was recovered in the bile, 11% in the urine, and 9% in the feces (Stearns et al., 2002) . Bile, urine, and the homogenate of feces were further analyzed by HPLC and LC/MS/MS. Although radiolabeled components in the urine eluted with the HPLC void volume, one component was identified tentatively on the basis of LC/MS/MS data as 2-hydroxy-2-pyridinylacetic acid (data not shown). In the feces, radioactivity recovered after oral dosing was attributed to the nonabsorbed parent compound, whereas three components were identified following intravenous dosing, with 1 being the predominant species (Fig. 2) .
The radiohistogram and HPLC-UV chromatogram of a bile sample from rats dosed orally with 3 H-labeled 1 are shown in Fig. 2 . Radiohistograms of the bile from rats treated by intravenous dosing were qualitatively similar to those following oral dosing (data not shown). Thus, six major drug-related components were identified and quanti-
FIG. 6. LC/MS/MS product ion spectra of M3 (A) from the bile from a rat dosed orally with 1 and (B) from an incubation of M5 with rat liver mitochondria.
The spectra were obtained by CID of the MH ϩ ion at m/z 627, and the proposed origins of key fragment ions are as indicated.
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at ASPET Journals on April 13, 2017 dmd.aspetjournals.org tatively estimated based on alignment of the radiohistogram with the HPLC chromatogram and LC/MS/MS analysis. The parent compound accounted for ϳ10% of the biliary radioactivity, and its characteristic MS/MS spectrum is shown in Fig. 1 for reference. Thus, the MH ϩ ion of 1 was present at m/z 625 and the predominant fragment ion at m/z 607 resulted from the loss of water. The fragment ion at m/z 487 was derived from the neutral loss of 1-amino-2-hydroxyethylpyridine, whereas the ion at m/z 305 was due to cleavage of the benzenesulfonamide bond with charge retention on the benzene side of the molecule. The metabolites M1 to M5 were designated according to their relative HPLC retention times (Fig. 2) .
Based on LC/MS analysis, M5 had an MH ϩ ion at m/z 519, 106 Da less than that of the parent compound, and was assigned as the carboxylic acid derivative resulting from N-dealkylation of 1 with loss of 1-amino-2-hydroxyethylpyridine (Fig. 3) . The prominent fragment ions at m/z 473 and 305 were attributed to the neutral loss of formic acid from the MH ϩ species and the cleavage of the benzenesulfonamide bond, respectively (Fig. 3) . M5 accounted for approximately 7% of the radioactivity in bile and 7% of the radioactivity in feces.
M1 was the most abundant component, accounting for ϳ55% of the radioactivity recovered in bile. The MH ϩ ion of M1 was observed at m/z 626, one mass unit higher than the MH ϩ ion of the parent compound, suggesting that the metabolite contained a different number of nitrogen atoms than the parent compound (Fig. 4) . This fact, in conjunction with new fragment ions at m/z 501 (MH ϩ Ϫ 125) and 126, both of which were consistent with the presence of taurine in the molecule, led to the assignment of M1 as the taurine conjugate of M5 (Fig. 4) . The fragment ion at m/z 258 was ascribed to cleavage of the sulfonamide bond with charge retention on the amino group, whereas prominent fragment ions at m/z 473 and 304 also were consistent with this structural assignment (Fig. 4) .
M2 constituted ϳ28% of the radioactivity in bile. The metabolite had an MH ϩ ion at m/z 641, 16 mass units higher than that of the parent compound, presumably due to the addition of an oxygen atom (Fig. 5) . The fragmentation pattern of M2 suggested that the modification had occurred on the pyridine functional group because the ion observed at m/z 151 in the product ion spectrum of the parent compound was shifted to m/z 167 (Figs. 1 and 5) . Proton NMR analyses of isolated M2 indicated that protons associated with hydroxyethyl portion of the molecule remained intact, but the pyridine protons had been shifted downfield (0.5-1 ppm) (data not shown). This metabolite therefore was assigned as the pyridine N-oxide derivative of 1.
M3 was a minor component accounting for ϳ4% of the biliary radioactivity and exhibited an MH ϩ ion at m/z 627, 1 mass unit higher than that of M1 and 2 mass units higher than that of the parent compound (Fig. 6A) . The CID spectrum of M3 produced a fragmentation pattern similar to that of M1, except that the ion at m/z 259 replaced the ion at m/z 258 (Figs. 4 and 6A ). This suggested that the difference of 1 mass unit between M1 and M3 was associated with the conjugating moiety, and possibly the amide linkage was replaced by an ester bond. On this basis, M2 was assigned tentatively as the isethionic acid conjugate of M5 (Fig. 6A) .
M4 accounted for ϳ2% of the radioactivity in bile and 16% of radioactivity in feces. The MH ϩ ion of M4 was at m/z 504, CID of which produced characteristic fragment ions at m/z 487 and 305 (Fig.  7) . These features, together with the absence of fragments derived from the hydroxyethylpyridine portion of the parent compound, led to the assignment of M4 as the primary amine resulting from Ndealkylation of 1 (Fig. 7) .
The identification of all metabolites was further confirmed by comparing their MS/MS spectra and HPLC retention times with those of the corresponding synthetic reference compounds.
Formation of the Taurine and Isethionic Acid-Conjugated Metabolites. The taurine and isethionic acid-conjugated metabolites, M1 and M3, were formed in incubations of M5 with rat liver subcellular fractions (microsomes and mitochondria) in the presence of ATP, CoA, and magnesium chloride, plus the corresponding conjugating component (taurine or isethionic acid) (Fig. 6B) . No conjugated metabolite was observed in control incubations containing boiled subcellular fractions or lacking ATP and CoA (data not shown). These data suggest that the conjugation reactions were mediated by the acyl-CoA thioester of M5 followed by acyl transfer to taurine or isethionic acid.
In the bile of a rat treated with M5, both M1 and M3 were identified as metabolites (data not shown), consistent with the hypothesis that M5 is the precursor to M1 and M3 during the metabolism of 1. In this experiment, an acyl glucuronide conjugate of M5 also was detected. The MS/MS spectrum of this metabolite consisted of a MH ϩ ion at m/z 695; a fragment ion at m/z 677, derived from loss of a water molecule; an ion at m/z 519, due to the neutral loss of 176 Da characteristic for glucuronides; and an ion at m/z 473, the result of combined neutral loses of glucuronic acid and formaldehyde (data not A, M1 was detected; B, both M1 and M3 were detected when the mouse was coadministered isethionic acid.
FIG. 9. HPLC-UV-vis chromatogram of samples from incubations of 1 with liver microsomes from (A) monkeys, (B) rats, (C) humans, and (D) dogs.
Identification of M2, M4, and M5 was based on comparison of HPLC retention times of the metabolites with those of synthetic reference compounds.
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at ASPET Journals on April 13, 2017 dmd.aspetjournals.org (Fig. 8A) . The isethionic acid conjugate M3, however, was identified only when the mouse was coadministered M5 plus isethionic acid (Fig. 8B ). This observation indicated that formation of M3 is speciesdependent, and the difference between rats and mice probably was due to differences in the availability of isethionic acid in liver tissue. Oxidative Metabolism of 1 in Incubations with Liver Microsomes. The HPLC-UV detection of oxidative metabolites formed in vitro was based on comparing HPLC retention times with those of synthetic reference compounds. Thus, M2, M4, and M5 were identified in incubations of 1 with rat, dog, monkey, and human liver microsomes, and qualitatively, the metabolite profile appeared to be similar among species (Fig. 9 ). An interesting note is that M5 was not found in incubations of M4 with liver microsomes from the four species (ϳ100% recovery of M4 following an incubation at 37°C for 30 min) whereas an aldehyde, derived from the deamination of M4, was observed when M4 was incubated with monoamine oxidase (data not shown).
Subsequent quantification by LC/MS/MS of oxidative metabolites formed in incubations of 1 with human liver microsomes was based on MRM detection of one characteristic mass transition per product in conjunction with HPLC retention times. The formation of M2 and M4 was linear over a period of 10 min, and incubations were therefore performed for 5 min. The apparent K m and V max values estimated for the formation of M2 were 29.4 M and 0.15 M/min/mg of protein, and the K m and V max values for M4 were 9.6 M and 0.11 M/ min/mg of protein. The formation profile of M5 in human liver microsomal incubations exhibited a substrate-inhibition (or metabolite-inhibition) pattern (data not shown).
In incubations of 1 with human liver microsomes, the formation of M2 and M4 was inhibited 40 and 79%, respectively, by troleandomycin, a selective CYP3A4 inhibitor (Table 1) . Inhibition of 1 metabolism also was produced by a monoclonal antibody against CYP3A4 (Table 1) . Both troleandomycin and the inhibitory antibody caused partial inhibition of the metabolism of 1 to M2. No effect was observed on the conversion of 1 to M2 and M4 with sulfaphenazole, a selective inhibitor for CYP2C9, and with quinidine, a selective inhibitor against CYP2D6 (Table 1) .
M2, M4, and M5 were detected in incubations of 1 with recombinant CYP3A4 but not in incubations with other recombinant P450 isoforms (data not shown).
Transport of 1 across Monolayers of Cells Expressing Pgp. A bidirectional transport assay was validated by examining the transport of [
3 H]vinblastine, an established Pgp substrate. In this case, transport of vinblastine from either side of the monolayer was linear over a period of 2 h, and the ratio for transport from B-to-A versus that from A-to-B was estimated to be ϳ7 (Fig. 10A) . Transport of 1 across the monolayer of cells expressing Pgp also was observed to be linear (Fig. 10B) , and the ratio for transport of the compound from B-to-A versus that from A-to-B was approximately 5. There was little movement of 1 through a monolayer of parent epithelial cells (controls) (Fig. 10B) .
Discussion
The systemic clearance of 1 in experimental animal species is moderate and can be accounted for mainly by hepatic extraction (Stearns et al., 2002) . When rats were treated with 3 H-labeled 1, most of the radiolabeled components were found in the bile with biliary radiochromatographic profiles being similar following either oral or intravenous administration. Studies of the biotransformation of 1 in 
2D6
100 100 a 1 in phosphate buffer was added to human liver microsomes suspended in phosphate buffer (0.1 M, pH 7.4) containing EDTA. The final concentration of the compound was 25 M. Sulfaphenazole and quinidine were preincubated with microsomes for 10 min, and troleandomycin was preincubated with microsomes in the presence of NADPH for 15 min at 37°C. Reactions were initiated by adding the substrate and another portion of NADPH and proceeded for an additional 10 min. The products were analyzed by LC/MS/MS.
b Anti-CYP 2D6 IgG or anti-CYP3A4 IgG was preincubated with microsomes for 30 min at room temperature. Control incubations contained preimmune IgG. Reactions were initiated by adding the substrate and another portion of NADPH and proceeded for additional 10 min. The products were analyzed by LC/MS/MS.
FIG. 10. Transport of (A) [ 3 H]vinblastine and (B) 3 H-labeled 1 across monolayers of cells expressing mouse mdr1a.
A wide separation between curves representing A-to-B versus B-to-A transport of 1 also was observed with human MDR1 (data not shown).
METABOLISM OF A THIAZOLE BENZENESULFONAMIDE DERIVATIVE
at ASPET Journals on April 13, 2017 dmd.aspetjournals.org rats therefore focused mainly on the identification of biliary metabolites.
In the bile from rats treated with 3 H-labeled 1, the taurine and isethionic acid conjugates of M5, namely M1 and M3, were identified. These metabolites also were observed in rats treated with M5 and were generated in vitro in incubations of M5 with rat liver subcellular fractions in the presence of ATP and CoA. These data suggest that M5 is the precursor of M1 and M3, and the formation of M1 and M3 from M5 follows similar mechanisms of amino acid conjugation reactions [i.e., M5 probably is converted to the corresponding acyl-CoA thioester intermediate followed by acyl transfer to taurine or isethionic acid (Fig. 11; Hutt and Caldwell, 1990) ].
The structural difference between the two conjugating components is that the amino group of taurine is replaced by a hydroxyl functionality in isethionic acid. Although hydroxyl groups theoretically can function as nucleophiles, very few examples have been reported on conjugation reactions of isethionic acid with carboxylic acid derivatives to form an ester bond (Lombardini, 1976) . Earlier data suggested that isethionic acid was derived from taurine in mammalian tissues, whereas further investigations indicated that the hydroxysulfonic acid was associated with the deamination of taurine by microorganisms (Welty et al., 1962; Fellman et al., 1980) . Isethionic acid also has been found in dietary constituents (Fellman et al., 1980) . In the case of M5, the isethionic acid conjugate was observed in rats but not in mice. This species difference was masked when the mouse was supplemented with isethionic acid, suggesting that the local availability of isethionic acid is the limiting factor in the formation of isethionic acid conjugates.
Although the taurine conjugate of M5 was a major metabolite, the acyl glucuronide of M5 was not observed in rats treated with 3 Hlabeled 1. In a generalized scheme, amino acid conjugation and acyl glucuronidation can be described as two competing reactions, with the former proceeding at lower K m and the latter possessing higher capacity (Mulder, 1990) . Accordingly, amino acid conjugation would be expected to be more important at low doses whereas acyl glucuronidation may become a major process at high doses (Mulder, 1990) . In rats treated directly with M5 (10 mg/kg, intraperitoneal injection), both the taurine conjugate and the acyl glucuronide were identified in bile. It appeared, therefore, that the absence of the glucuronic acid conjugate in rats administered 1 (10 mg/kg, oral dosing with ϳ30% absorption) may have been the result of limited M5 available for glucuronidation.
With respect to M5, this metabolite may result from either the N-dealkylation of 1 by loss of 2-hydroxy-2-pyridinylethylamine or from further metabolism of M4 (Fig. 11) . In incubations with liver microsomes from rats, dogs, monkeys, and humans, M5 was detected only when 1 was used as the substrate. Although the precise mechanism is not known, the formation of M5 in these incubations was observed to be NADPH-dependent, implicating a role for P450 enzymes in the conversion of 1 to M5. One such enzyme may be human hepatic CYP3A4, because M5 was identified in incubations of 1 with the recombinant P450 isoform. On the other hand, M5 might also derive from the deamination of M4. Although M4 appeared not to be metabolized in a system containing liver microsomes plus NADPH, an aldehyde product was detected in incubations of M4 with monoamine oxidase. It may be speculated that further oxidation of the aldehyde results in the formation of M5 (Fig. 11) .
The formation of M2 and M4 in incubations of 1 with liver microsomes from rats, dogs, monkeys, and humans was observed to be NADPH-dependent, suggesting the involvement of P450 enzymes. Metabolite profiles were similar across species. In human liver microsomal incubations, apparent K m and V max values estimated for the formation of M2 were 29.4 M and 0.15 M/min/mg of protein, and for M4, 9.6 M and 0.11 M/min/mg of protein. These reactions were inhibited by troleandomycin and by a monoclonal antibody against CYP3A4 but were not influenced by sulfaphenazole and quinidine. The two metabolites also were identified in incubations of 1 with recombinant CYP3A4. Taken together, these data indicate that human hepatic CYP3A4 catalyzes the metabolism of 1 to M2 and M4. On the other hand, the incomplete inhibition observed in the case of M2 implicates a role for P450 isoforms other than CYP3A4, or of nonP450 enzyme(s), in the formation of this metabolite.
An interesting observation was that approximately 10% of the dose was recovered in the feces from bile duct-cannulated rats administered 3 H-labeled 1 by intravenous injection. Since all the bile flow was transferred to collection vials, the parent compound found in the feces was most likely due to intestinal excretion. Subsequent investigation in a bidirectional transport in vitro assay indicated that transport of 1 across a monolayer of cells expressing mouse mdr1a or human MDR1 was similar to that of vinblastine, suggesting that this ␤ 3 -receptor agonist was a substrate of the Pgp transporter. It may be speculated, therefore, that 1 is subject to excretion by the Pgp transporter localized in rat intestine. Similar data were reported for the disposition of digoxin in mice, wherein the drug was found to be excreted via the intestinal mucosa by Pgp proteins (Mayer et al., 1996) .
In summary, five major metabolites of 1 were identified in rats, including a pyridine N-oxide derivative M2, a primary amine M4, a carboxylic acid M5 and its corresponding taurine conjugate M1, and isethionic acid conjugate M3. The formation of M2, M4, and M5 most likely is the result of P450-catalyzed metabolism. Further biotransformation of M5 leads to the formation of M1 and M3, which may follow a similar mechanism as that for amino acid conjugation. A small amount of 1 recovered in the feces of bile duct-cannulated rats following intravenous dosing could be due to intestinal Pgp-mediated excretion of the parent drug.
